BioImagene appoints Dr. Ajit Singh as CEO
Founder and current CEO Mohan Uttarwar to take on the role of Chief Strategy Officer
Cupertino, CA, September 17, 2008
BioImagene, the
leading provider of innovative and affordable digital pathology
solutions for cancer diagnosis and pre clinical research,
today announced the appointment of Ajit
Singh, Ph.D. as Chief Executive Officer (CEO). Dr. Singh
had joined the Board of Directors of the company in July
2008, prior to the closing of the $26M expansion financing
round. He will assume the CEO role starting October 6th,
2008.
The founder and the current CEO, Mohan
Uttarwar will remain with the company, serve on the
Board of Directors, and take on the role of Chief Strategy
Officer.
Mr. G. Steven
Burrill, Chairman of the Board of BioImagene said “We
are delighted to have Ajit at the helm of BioImagene. The
company has established itself as a clear innovation leader
in Digital Pathology over the past years, and is well positioned
to lead the market. Ajit brings with him tremendous experience
in the area of Oncology, Medical Imaging, Healthcare Information
Systems, and Knowledge Based Medicine. Digital Pathology
sits exactly at the nexus of these fields.”
Dr. Singh’s most recent position was as the CEO of
the Image and Knowledge Management business of Siemens Healthcare,
based in Germany. He has spent nearly twenty years at Siemens
in various roles. Prior to taking on his current responsibility
in 2006, he was the CEO of the Oncology Care Systems business
of Siemens for five years, based in California. He
has a Ph.D. in Computer Science from Columbia University.
”We are very fortunate to have the insight and experience
that Ajit brings to the table,” said Mohan Uttarwar
founder and CEO, BioImagene. “I look forward to working
closely with him to help BioImagene achieve a dominant position
in digital pathology,” he added.
Dr Ajit Singh said, “I am excited about joining BioImagene.
The company has led the way in innovation – both in
technology and in business models. It is time to stimulate
a widespread adoption of Digital Pathology. I view this as
an ‘industry shaping’ exercise.”
Mr.
Yatin Mundkur, a partner at Artiman Ventures, one of
the early investors in BioImagene commented, “We
are proud of what BioImagene has achieved in such a short
time under the leadership of Mohan Uttarwar. With innovations
in biomarker discovery and imaging, digital pathology is
at the threshold of going mainstream. Having known Ajit
for many years, I am thrilled that we have him on the team
as we enter this next phase of growth.”
About BioImagene, Inc.
BioImagene is a leading provider of
total digital pathology solutions for applications including
clinical diagnostics and drug discovery. BioImagene products
are FDA -cleared for specific clinical applications, and
are intended for research use for other applications. www.bioimagene.com.
Media contact: Suchi Parth, 408 207 4285
|
